Statement of Changes in Beneficial Ownership (Form 4)

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Islam Saqib 2. Issuer Name and Ticker or Trading Symbol SpringWorks Therapeutics, Inc. [SWTX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Executive Officer (Last) (First) (Middle) C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BLVD. 3. Date of Earliest Transaction (Month/Day/Year) 02/12/2025 (Street) STAMFORD, CT 06902 4. If Amendment, Date Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock(1)(2) 02/12/2025 A(1)(2) 85,309 A $ 0 1,087,811 D Common Stock 02/12/2025 F 13,186 D $59.28 1,074,625 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Islam Saqib C/O SPRINGWORKS THERAPEUTICS, INC. 100 WASHINGTON BLVD. STAMFORD, CT 06902	X		Chief Executive Officer

Signatures

/s/ Francis I. Perier, Jr. as Attorney-in Fact		02/14/2025
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	This transaction represents the issuance of performance restricted stock units ("PSUs"). Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. The PSUs were originally granted on January 5, 2023, subject to the achievement of a certain performance based milestone within four years from the grant date, which milestone was achieved as a result of approval by the U.S. Food and Drug Administration of the Issuer's product candidate, GOMEKLI(TM), for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas.
(2)	28,436 PSUs shall vest immediately upon issuance, another 28,436 PSUs shall vest on the date that is 12 months following February 12, 2025 and the remaining 28,437 PSUs shall vest on the date that is the later of (i) 24 months following February 12, 2025 or (ii) the Measurement Period End Date (as defined below), subject to continued service to the Issuer by the Reporting Person as of each such vesting date; provided that, such remaining 28,437 PSUs shall be subject to an upwards or downwards adjustment described in the PSU award agreement. As used herein, "Measurement Period End Date" means the first to occur of (i) December 31, 2026 or (ii) the date of consummation of a Sale Event (as defined in Issuer's 2019 Stock Option and Equity Incentive Plan).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Public link

Please use the above public link if you want to share this noodl on another website.